InNexus Biotechnology, Inc.

OTCPK:IXSB.F Stock Report

Market Cap: US$154.0

InNexus Biotechnology Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenureno data
Board average tenure17.6yrs

Recent management updates

No updates

Recent updates

No updates

CEO

InNexus Biotechnology has no CEO, or we have no data on them.

Board Members

NamePositionTenureCompensationOwnership
Jur Strobos
Vice President of Clinical & Regulatory Affairs and Member of Scientific Advisory Boardno datano datano data
Daniel Von Hoff
Member of Scientific Advisory Boardno datano datano data
Carlos Arteaga
Member of Scientific Advisory Board17.7yrsno datano data
Ronald Levy
Member of Scientific Advisory Boardno datano datano data
J. Capra
Chairman of Scientific Advisory Board17.8yrsCA$27.60kno data
Maurizio Zanetti
Member of Scientific Advisory Board17.1yrsno datano data
Leroy Chiao
Independent Director18.1yrsCA$64.54kno data
John Minna
Member of Scientific Advisory Boardno datano datano data
Martin Weigert
Member of Scientific Advisory Board17.6yrsno datano data
Ellen Vitetta
Member of Scientific Advisory Boardno datano datano data
Judith James
Member of Scientific Advisory Board17.1yrsno datano data

17.6yrs

Average Tenure

72yo

Average Age

Experienced Board: IXSB.F's board of directors are seasoned and experienced ( 17.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/23 20:24
End of Day Share Price 2024/11/07 00:00
Earnings2011/03/31
Annual Earnings2010/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

InNexus Biotechnology, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David DeanCormark Securities Inc.